Gene · 3799
Papers2,390
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
141 to 160 of 2,390
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MET fusions are targetable genomic variants in the treatment of advanced malignancies. | Cell Commun Signal | 2024 | 38195556 | PubTator, text mining | PubMed |
| The outcomes of different regimens depend on the molecular subtypes of pulmonary large-cell neuroendocrine carcinoma: A retrospective study in China. | Cancer Med | 2024 | 38180312 | PubTator, text mining | PubMed |
| Histiocytosis Presenting as Bilateral Adrenal Masses: A Case Report. | Case Rep Oncol | 2024 | 38179548 | PubTator, text mining | PubMed |
| Combination of TrxR1 inhibitor and lenvatinib triggers ROS-dependent cell death in human lung cancer cells. | Int J Biol Sci | 2024 | 38164168 | PubTator, text mining | PubMed |
| FDA-approved heterocyclic molecules for cancer treatment: Synthesis, dosage, mechanism of action and their adverse effect. | Heliyon | 2024 | 38163206 | PubTator, text mining | PubMed |
| Organelle morphology and positioning orchestrate physiological and disease-associated processes. | Curr Opin Cell Biol | 2024 | 38096602 | PubTator, text mining | PubMed |
| Autophagy in Disease Onset and Progression. | Aging Dis | 2024 | 37962467 | PubTator, text mining | PubMed |
| Role of lysosomal trafficking regulator in autophagic lysosome reformation in neurons: a disease perspective. | Neural Regen Res | 2024 | 37862187 | PubTator, text mining | PubMed |
| Novel ALK immunohistochemistry assay (clone OTI1A4, Dako) is a sensitive, reliable marker for identifying ALK rearrangements in lung adenocarcinomas: A validation study. | Am J Clin Pathol | 2024 | 37681660 | PubTator, text mining | PubMed |
| Clinical and genomic analysis of baseline and acquired MET fusions with an intact kinase domain in lung cancer patients. | Genes Dis | 2024 | 37588206 | PubTator, text mining | PubMed |
| Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report. | Anticancer Drugs | 2024 | 37450292 | PubTator, text mining | PubMed |
| MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition. | J Thorac Oncol | 2024 | 37429463 | PubTator, text mining | PubMed |
| Interaction of Tau with Kinesin-1: Effect of Kinesin-1 Heavy Chain Elimination on Autophagy-Mediated Mutant Tau Degradation. | Biomedicines | 2023 | 38275365 | PubTator, text mining | PubMed |
| Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report. | Front Immunol | 2023 | 38235141 | PubTator, text mining | PubMed |
| An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: a case report. | Transl Lung Cancer Res | 2023 | 38205210 | PubTator, text mining | PubMed |
| Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001. | Cancers (Basel) | 2023 | 38201566 | PubTator, text mining | PubMed |
| Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs. | Cancers (Basel) | 2023 | 38201460 | PubTator, text mining | PubMed |
| Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. | Cells | 2023 | 38201251 | PubTator, text mining | PubMed |
| Addition of Trastuzumab Deruxtecan to Selpercatinib in a Patient With RET Fusion-Driven NSCLC and an Acquired HER2 Amplification: Case Report. | JTO Clin Res Rep | 2023 | 38144396 | PubTator, text mining | PubMed |
| Inflammatory myofibroblastic tumor of the submandibular gland Harboring MSN-ALK gene fusion: A case report and literature review. | Heliyon | 2023 | 38144359 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3799/papers?page=8